FTC Opioid Addiction Treatment Suboxone Settlement

UPDATE 2:

• Top Class Actions viewers reported receiving payments for as much as $2,563.92 as of mid-May 2021.
• Congratulations to everyone who submitted a claim and got paid!

UPDATE:

• According to the settlement website, checks were mailed to approved claimants on May 10, 2021.
• Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

A $60 million settlement has been reached between the makers of the opioid addiction medication Suboxone and the Federal Trade Commission.

According to the FTC, Indivior Inc. and its subsidiary Reckitt Benckiser Group, conspired to prevent a lower-priced generic version of Suboxone from interfering with its significant pharmaceutical sales.

The settlement benefits all U.S. consumers who were prescribed Suboxone Film between March 1, 2013 and Feb. 28, 2019. The payout amount will depend on the number of total claims filed and how long the consumer was prescribed Suboxone film.

The FTC anticompetitive lawsuit notes that Indivior falsely marketed its Suboxone Film as being “less susceptible to accidental pediatric exposure than Suboxone Tablets,” right before a generic version of Suboxone tablets entered the market.

This misleading claim reportedly forced many consumers to switch to Suboxone Film which was the more expensive option.

The FTC states that Indivior even went so far as to submit a petition to the Food and Drug Administration in 2012 with statements that “Suboxone Tablets had been discontinued due to safety concerns about the tablet formulation of the drug.”

“In the midst of the nation’s opioid crisis, a critical opioid-addiction treatment was about to become more affordable,” said Gail Levine, a Deputy Director of the FTC’s Bureau of Competition. “But Indivior prevented that. It kept its drug prices high by unlawfully impeding generic manufacturers from competing effectively.”

The Suboxone lawsuit claims that Indivior engaged in improper business practices that didn’t allow competition thus violating Section 5 of the FTC Act.

Under the terms of the FTC settlement, consumers must file a claim no later than Dec. 1, 2020 to get a refund check.

Who’s Eligible

U.S. consumers who were prescribed Suboxone Film between March 1, 2013 and Feb. 28, 2019 are eligible to file a claim for this FTC settlement.

Potential Award

Varies. 

The payout amount depends on how long the consumer took Suboxone and how many claims are submitted overall.

Proof of Purchase

Not required at this time. However, consumers are encouraged to save any supporting documents in case the settlement administrator has questions later on.

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

12/1/2020

Case Name

FTC v. Indivior, Case No. 1:20-cv-00036-JPJ-PMS, and FTC v. Reckitt Benckiser Group PLC, Case No. 1:19-cv-00028, both in the U.S. District Court for the Western District of Virginia, Abingdon

Final Hearing

N/A

Settlement Website

SuboxoneClaimsCenter.com

Claims Administrator

Suboxone Claims Center
c/o JND Legal Administration
P.O. Box 91356
Seattle, WA 98111
Info@SuboxoneClaimsCenter.com
1‑877‑545‑0238

Class Counsel

Markus H. Meier
Bradley Albert
Daniel Butrymowicz
Matthew Weprin
FEDERAL TRADE COMMISSION

Defense Counsel

Read About More Class Action Lawsuits & Class Action Settlements:

FTC Refund Checks | July 2020

A Guide to the Negative Impacts of OxyCide Cleaner

FTC Refunds | June 2020

Ethicon Surgical Staplers Recalled by Manufacturer